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Interim analyses of clinical trial data are frequently used to provide evidence to obtain marketing authorisation for new drugs. However, results from such analyses may not reflect true estimates of relative effectiveness when trial follow-up is complete. Survival results, available at two time points from a breast cancer clinical trial were compared to test the hypothesis that using immature data and a widely-used right-censoring rule leads to biased survival estimates.
Kaplan-Meier progression-free and overall survival data from two published CLEOPATRA trial reports (2012 and 2014) were digitized. Overlaying these results highlighted divergent trends. Parametric functions were fitted to both data sets but did not indicate consistent patterns which could be used as a basis for long-term extrapolation.





In April 2014 Medical Decision Making published an article in which we outlined our approach to analysing and extrapolating survival data used to support health technology appraisals.[1] Here we expand on one of the issues which we identified in that article. Namely, the general practice of censoring incomplete patient records in clinical trials at the time of last observation (rather than at the date of data cut-off), which we consider involves a substantial risk of bias in interim analyses of time-to-event trial data. In this article we illustrate how this practice can result in misleading estimates of relative effectiveness. A comparison of published results [2, 3] from two data-cuts of the CLEOPATRA trial provides an example of both the nature and magnitude of the unintended bias that arises from censoring at the time of last observation. We also explore how inappropriate censoring can impact on cost-effectiveness results by influencing the selection of parametric models used as a basis for extrapolating incomplete clinical trial survival data. 
Censoring truncated trial data
It has become common practice for interim results of clinical trials of promising new cancer treatments to be reported very early, sometimes even before median survival can be estimated for both arms of the trial. Since a large number of recruited patients are still actively treated at the time of data cut-off, there is considerable scope for interim results to be influenced by the rule applied to manage the truncated data. The effect is further exacerbated by the fact that an extended recruitment period is frequently needed to reach the required number of eligible patients for the study. The application of a common cut-off calendar date for an interim analysis leads to some data available from the beginning of the study being analysed together with data from patients who have only recently been recruited.
Censoring in the CLEOPATRA trial was applied to patients still at risk at the time of data cut-off using the last date on which each patient was known to be alive for overall survival (OS), and the date of the last Interferon Regulatory Factor evaluable tumour assessment for progression-free survival (PFS).[4] This approach to censoring incomplete time-to-event data is generally accepted as an industry standard. However, it is rarely recognised that this method of analysis involves an imbalance between the possible risk of inadvertently omitting a final event for some of the censored patients, and the certainty of reducing the measured time at risk for all censored patients. 
The practice of re-censoring a patient record to the date last seen in clinic (rather than the date of data cut-off) assumes that a patient’s status cannot be determined. It also assumes that such re-censoring does not materially influence the results of survival analysis. Both assumptions are questionable.
Determining patient status
In a well-run clinical trial, there should be multiple means available to verify a patient’s vital status (OS) at data cut-off, including formal notification of death, recorded contacts or correspondence with the patient, brief telephone calls to family members or a family physician, or notification from the patient that they wish to withdraw from the trial. The risk of failing to identify a patient death prior to cut-off should, therefore, be minimal. The CLEOPATRA trial protocol requires that prior to final analysis “the investigative sites will contact every patient who is on study to confirm current survival status”[4] but there is no such requirement prior to any interim analyses being conducted. This omission is the prime source of uncertainty in  interim analysis results.
PFS is confirmed by three possible actions: self-reported symptomatic disease progression through communication with the trial physician or the family physician, periodic specialist diagnostic testing, and death. Thus, interim analyses of PFS data will be affected by both the lack of accurate survival status determination and problems in identifying the time of disease progression accurately.

How standard re-censoring practice affects survival results
Product-limit survival estimation involves calculation of the probability of event-free survival for each time period between consecutive events, and accumulating those probabilities by multiplication as follows:

     Estimated survival at time t, 
                                                F(t)  =  i{1 – e(i) / r(i) }, 
for i = periods between distinct recorded event times less than or equal to t, 
e(i) = number of events recorded to occur at the end of period i, 
r(i) = number of patients at risk at the beginning of period i

If a patient is event-free at the time of data cut-off then, when estimating F(t), that patient would be included in the at-risk patient count, r for the final (1–e/r) component. 
However, the commonly applied censoring method uses an earlier date for censoring, the date when the patient was ‘last known to be event-free’. If this date occurs for a patient at, or before, the penultimate recorded event, it reduces the value of r by 1 for the final (1 – e/r) component of the F(t) calculation. Since the number of events e is unchanged by this modification, the value of the e/r ratio is increased so that the estimated relative event-free survival is reduced, leading to a smaller estimated survival F(t) at time t.
If the time ‘last known to be event-free’ for a patient at risk at the time of data cut-off moves the censoring time back across multiple preceding calculation segments, then the change to the number of patients at risk also reduces the value of (1 - e/r) in each of the following segments. As a result, the under-estimation of F(t) from censoring a single patient record may accumulate over time by multiplication, increasing the introduced bias. This logic applies, irrespective of the reason for censoring, if the same method is used to ‘write-back’ the time of censoring to an earlier ‘last known to be event-free’ time.
It may be claimed that this practice of excluding exposure time prior to data cut-off is conservative and, therefore, justifiable. However, this view is based on an inadequate interpretation of the information available about patients who are event-free at data cut-off. For such patients we know that no notification has been entered onto the central trial database regarding whether an event has occurred between the last recorded event-free contact and the interim analysis cut-off date. This does not exclude the non-zero probability that the event did occur but that the information was not available for analysis, since “absence of evidence is not evidence of absence.” 
However, we can generally assume that the probability that a missing event has occurred prior to data cut-off is likely to be small, since the need to undertake an interim analysis, well in advance of the planned trial closure date, implies that the event accrual rate is low. 
In Figure ZZ, the data for the initial phase of a patient’s trial experience (S to A) can be assumed to be accurate and complete both for event status and for the length of time the patient was exposed to the risk of an event occurring. By contrast, in the following period until data cut-off (A to B) there is a small probability that the event count (e) is understated, but a large complementary probability that the patient’s exposure to risk (r) will be seriously understated if all exposure time between A and B is excluded from the product-limit calculations, as in conventional censoring.

Figure 1. Timeline of trial patient still at active and at risk of event (death or disease progression) at data cut-off 
It is important to note that for the final trial analysis a specific mechanism was included in the CLEOPATRA trial protocol[4] to require every recruiting site to actively trace the final status of every patient at the trial termination date, ensuring that the events recorded are fully synchronized with the time at risk for every patient. There is no such requirement in respect of interim analyses, allowing incomplete event data to be combined with conventional censoring to generate biased survival estimates.
Cancer case study
In 2015 the New England Journal of Medicine (NEJM) published results from the CLEOPATRA trial of pertuzumab, trastuzumab and docetaxel for the treatment of human epidermal growth factor-2 (HER-2) positive metastatic breast cancer.[2]  Between February 2008 and July 2010 a total of 808 patients were randomized 1:1 to either a pertuzumab+trastuzumab+docetaxel regimen or to placebo+trastuzumab +docetaxel. The published results were generated from data available in February 2014, with a maximum follow-up of 70 months.
Prior to the publication of these results, the trial sponsor (F. Hoffmann-La Roche Ltd.) had been asked by the European Medicines Agency (EMA) to carry out an interim analysis with a cut-off date in May 2012. The results from this interim analysis were published in 2013 [3], and formed the basis of a submission to the UK National Institute for Health and Care Excellence (NICE), to inform the Single Technology Appraisal (STA) considering the clinical and cost effectiveness of pertuzumab in combination with trastuzumab and docetaxel.[5]
This sequence of events has provided an opportunity to compare the results of time-to-event outcomes between the 2012[3] and 2014[2] analyses. In particular, it allows consideration of how the most widely-used censoring rule used in interim analyses affects in-trial survival estimates, as well as long-term survival gains estimated by parametric extrapolation modelling.

Methods
We derived results from the 2014 data analysis of the CLEOPATRA trial by digitizing the Kaplan-Meier curves published in the New England Journal of Medicine [2] for OS and PFS. Similarly, data from the 2012 analysis were digitized from product-limit charts for OS and PFS in the Lancet Oncology paper.[3] Graphical comparison of Kaplan-Meier analyses from the two data-cuts was used to identify the time at which divergence between the 2012 and 2014 OS and PFS trends emerges. This divergence corresponds to the time at which end-point censoring was applied in each analysis (20-25 months from randomization in 2012, and 40-45 months in 2014).




In any clinical trial there is an unavoidable on-going risk that some patients will be lost to follow-up for a number of reasons including withdrawal on medical advice, and a variety of unanticipated personal circumstances. When combined with the risk of trial events (death or disease progression), this results in the premature censoring of some patients’ data and a consequent reduction in the number of patients remaining at risk over time. However, when an interim data analysis is performed before the planned closure of the trial, there is a substantial increase in the rate at which ‘at risk’ patient numbers decline. This reflects the extended period over which new patients are recruited before the target number of trial participants is achieved.
This effect can be observed in a plot of OS data from the CLEOPATRA trial [2] (Figure 2A). In both trial arms there is an initial period of relatively low attrition in the numbers of patients at risk of death, followed by a sharp increase in the rate at which patients drop out of the trial. Since the mortality risk is relatively stable in each trial arm during the initial trial period (Figure 2B), the sudden change in trends must be attributed to right-censoring of a substantial number of cases at the time of the data-cut. In the 2012 data this effect occurred between 20 and 25 months, and in the 2014 data between 40 and 45 months, corresponding closely to the elapsed time between the data-cuts of 20.96 months.
Progression-free survival and overall survival
Figures 3A and 3B allow comparison of the Kaplan-Meier estimates of PFS using the 2012 and 2014 data-cuts. It is apparent that there is close correspondence between the two sets of data for the first two years of the trial. During the third year a widening gap opens; this is especially evident for patients treated with pertuzumab, and corresponds to the time during which data from an increasing number of patients were right-censored. The 2012 and 2014 hazard trends displayed in Figure 2B are particularly revealing. They demonstrate how the conventional right-censoring rule artificially accelerates the rate of disease progression in the 2012 data. Of especial interest is the very close similarity of hazard gradients in the trial arms of the 2014 data, suggesting that after two years patients remaining at risk in both arms are subject to similar long-term risks of disease progression, which is contrary to the apparent trend divergence seen in the 2012 data.
Likewise, data displayed in Figures 4A and 4B indicate an equivalent pattern of suddenly increased mortality risk after two to three years. In contrast to the 2012 data, the longer-term OS data from the 2014 data-cut show steady continuing trajectories across five years of follow-up.
However, comparison of results for PFS (Figure 3A) and OS (Figure 4A) suggests that the impact of censoring bias may not be consistent or predictable. In Figure 3A the 2012 data-cut shows a sharp narrowing of the gap between the treatment arms in the final six months of PFS follow-up, whereas Figure 4A shows a clear widening of the gap in the same period of OS follow-up. The more mature 2014 data-cut reveals that these trend changes in the earlier data are not reliable indicators of the longer-term experience of patients still at risk. This calls into question the use of these heavily censored trial data to fit parametric survival functions for the purpose of extrapolating the lifetime net benefit of a new treatment regimen.
Table 1 presents the difference in mean OS between the intervention and the comparator arms, estimated by the area-under-curve (AUC) method, at the maximum common time point (184 weeks from randomization), using data from the two data-cuts. The more mature data yield a 9% reduction in the estimated mean OS advantage attributable to treatment with pertuzumab+trastuzumab+docetaxel versus placebo+trastuzumab+docetaxel solely due to the widening separation of OS trends in the earlier data-cut being replaced by parallel OS trends in the 2014 data (Figure 4A).
Another statistic of interest is the estimated HR for effect of pertuzumab+trastuzmab compared to placebo+trastuzumab; this metric indicates the relative clinical effectiveness of the intervention therapy and is often used in cost-effectiveness decision models. Analysis of OS data from the 2012 data-cut results in a HR of 0.651 (95% confidence interval [CI]: 0.644 to 0.658), whilst the corresponding HR result from the 2014 data-cut is 0.681 (95% CI: 0.676 to 0.687). Comparison of the two HR results shows that the relative effectiveness of the intervention and comparator is statistically significantly poorer when estimated using the more mature data.
Extrapolation modelling
When constructing decision analytical models it is common practice to experiment with fitting one of a limited number of standard parametric survival functions to clinical trial data and then to use the survival function that best matches the available trial evidence as the basis for populating a decision model. Table 2 shows the relative success of curve-fitting (as indicated by the Akaike information criterion [AIC]) for both outcomes (PFS and OS), for both treatment regimens (pertuzumab+trastuzumab+docetaxel and placebo+trastuzumab+docetaxel), and using data from both published data-cuts (2012 and 2014). There is no obvious consistency between the results from the two sets of data: for PFS, the same function (log logistic) is preferred for the placebo arm, but not for the pertuzumab arm. For OS, the same function (log logistic) is preferred for the pertuzumab arm, but not for the placebo arm. Only one result is consistent across all combinations – that the simple exponential model is not appropriate for modelling any of the available data sets.
If the best-fitting parametric functions are extrapolated to a 10-year horizon, the estimated mean OS gain attributed to pertuzumab combination treatment increases to 17.69 months based on the 2012 data cut, but to only 12.03 months using the more mature 2014 data cut. Thus parametric extrapolation using the immature data cut exaggerates the survival gain by at least 47%, resulting on a severe distortion of the apparent cost-effectiveness of the new combination treatment. This reduces the incremental cost-effectiveness ratio by about one third. 

Discussion
There is increasing pressure on clinical researchers to report interim results from clinical trials of new treatments as early as possible, and for regulators and service providers to make decisions on licensing and reimbursement long before mature results can be obtained. In this environment, it is important that interim analyses are carried out with careful regard to the potential risk of obtaining results which subsequently prove to have been ill-founded. We have shown that the most widely used method for censoring trial data from patients still at risk when an immature data-cut is analysed results in the very real possibility that effective treatments may be rejected inappropriately, or that ineffective treatments are approved on the basis of flawed incomplete evidence. 
Although both the European Medicines Agency (EMA) [6] and the US Food and Drug Administration (FDA) [7] provide guidance relating to the avoidance of ‘informative censoring’ in the analysis of clinical trial data, both limit consideration to PFS (and similar compound outcomes) without mention of OS, for which no specific method of right-censoring is discussed.
It is important to recognise that the censoring bias described here is quite distinct from conventional ‘informative censoring’ and is related specifically to the disparity in the quality of data used for interim analyses immediately prior to data cut-off, compared to that on which final analyses are based. Moreover its effects are equally likely to be seen in interim analyses of all types of time-to-event outcome data, and are not limited to compound variables such as PFS.
The results available from the CLEOPATRA trial [2], [3] clearly demonstrate the importance of the type of censoring applied to any cases still at risk at data cut-off. In particular, the degree of trend bias is most clearly seen in the extent and timing of premature censoring in early data cuts. 
The impact of early termination of clinical trials when an interim data analysis suggests a significant benefit for the intervention therapy compared to existing treatments has been reported in papers by Pocock and Hughes [8], and subsequently by Bassler et al [9] and Guyatt et al [10], and was reported as generally inflating the estimated relative benefit of a new treatment. However, the phenomenon described here is quite separate from concerns about early termination. Although the practice of censoring incomplete records by ‘writing back’ the time of censoring to the time of a prior administrative event (such as the most recent clinic visit) always operates to increase the estimated hazard rate during the final segment of the data set, its effect is not necessarily consistent across the arms of a clinical trial. It can give rise to either exaggerated net survival benefit or net loss depending on the balance and timing of patients whose data is subject to this type of censoring.
The published CLEOPATRA trial results [2], [3] show how this bias can significantly impact on the estimation of the HR, to either increase or decrease the estimated magnitude of benefit attributable to the novel treatment. Moreover, we have shown that the selection of a suitable parametric function for extrapolating incomplete data series may be misdirected by the choice of a particular censoring method.
A particular concern is that the presence of unrecognised censoring bias may prevent the identification of alternative model formulations which better explain the causal dynamics of response to treatment than the widely used standard statistical formulations. The CLEOPATRA trial results [2], [3] provide a good example of this phenomenon. Figure 5A and 5B demonstrate how a non-standard pattern of mortality hazard matches the 2014 data-cut closely. This indicates that in both trial arms mortality rates are suppressed during the first 12 months of the trial, then increase to a continuing constant risk to the end of the observation period. The initial mortality rate for patients receiving pertuzumab is 6.6% compared to 10.6% in the placebo arm (a reduction of 37% from treatment with pertuzumab); the continuing mortality rates are 15% and 21% respectively (a reduction of 29%).
In our experience, when challenged on this issue some companies respond by claiming that the ‘last time seen’ method of right censoring is conservative and therefore likely to understate the estimated benefit attributable to their product. However, our analysis of the CLEOPATRA reported results indicate that although PFS and OS are understated in both trial arms, the effect is variable and can as easily lead to overstating relative treatment effectiveness as to understating it.
We conclude that the conventional method used to censor trial data from patients still at risk when an immature data-cut is analysed, has been shown to be prone to systematic bias. We consider that alternative censoring rules should be explored as standard analytic practice, to indicate the extent of uncertainty associated with the censoring method applied in interim analyses of trial data.





	Restricted mean OS (months) after 184 weeks










	Pertuzumab, trastuzumab and docetaxel	Placebo, trastuzumab and docetaxel	Pertuzumab, trastuzumab and docetaxel	Placebo, trastuzumab and docetaxel
Outcome	Model	AIC	Model	AIC	Model	AIC	Model	AIC
PFS	Log Logistic	-631.3	Log Logistic	-447.3	Log Normal	-523.8	Log Logistic	-329.3





OS	Log Logistic	-513.7	Weibull	-629.4	Log Logistic	-359.4	Log Logistic	-290.5
	Weibull	-512.2	Gompertz	-565.4	Gamma	-348.1	Gamma	-274.4




Models in descending order of preference according to estimated Akaike Information Criterion (AIC) score, using Burnham & Anderson method [9]







NB  Figures 2A & 2B should be shown together – either side by side, or one above the other.  Similarly Figures 3A & 3B,  and Figures 4A & 4B
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